Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Vascul Pharmacol. 2021 Jun 9;139:106881. doi: 10.1016/j.vph.2021.106881

Figure 2. Ang-II activates inflammasome in vascular smooth muscle cells.

Figure 2.

Immunoblots of NLRP3 (A), pro-caspase 1 (p40) and active Casp1 (p20) (B) and pro and mature IL-1β (C) and immunoblot representatives (D) in rat aortic vascular smooth muscle cells (RASMC) treated with Ang-II (0,1 μM) for 8 h or 24. h, or LPS+Ang-II (500 ng/mL for 6 h followed by Ang-II 0,1 μM for 60 min) or Ang-II+Nigericin (Ang-II 0,1 μM for 6 h followed by Ang-II 0,1 μM for 60 min). N= 5 to 9. Values are reported as mean ± s.e.m. *P<0.05 vs. vehicle.